Elysian Capital III LP acquisition with management of IMS Euro Group Limited

Elysian Capital III LP is pleased to announce, in conjunction with management, its acquisition and investment in IMS Euro Group Limited, “IMS”. This represents the eighth platform investment in the Elysian Capital III LP Fund which closed in September 2020 at £325million.

IMS supplies medical and non-medical consumables to the veterinary sector in the UK and Europe, having recently set up an operation in The Netherlands serving customers across Northern Europe.

Led by Sam Collard, who became CEO in 2023 having joined as CFO, the business has grown significantly in recent years supported by strong tailwinds of veterinary clinic consolidation, growth in pet ownership and increasing penetration of pet insurance driving growth in the number of procedures and therefore increased consumables requirements.

Sam Collard, CEO said: “We are delighted to have Elysian’s support in enabling us to build on our position as a leading provider of high quality, cost-effective medical consumables across the UK and Europe and in establishing IMS as the medical consumables partner of choice - Our vision remains to be the number one global supply partner for all veterinary and medical professionals and this partnership marks another milestone on that journey.”

David Colclough, Partner at Elysian Capital said: “We are excited about this partnership with Sam and the IMS team. We have been struck by the market leadership shown by the business, its customer-centric focus and approach to high quality innovative products of exceptional value. We look forward to working closely with IMS on the next stage of its journey.”

Elysian Capital was advised by: DWF (legal); Aon (insurance); PwC (tax); EY Parthenon (commercial); KPMG (financial).